ClinicalTrialsFinder

EGFR Exon 20 Insertion Mutations Clinical Trials in New York, New York

1 recruitingNew York, New York

Showing 1–1 of 1 trials

Recruiting
Phase 1

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Solid TumorsNSCLCEGFR Exon 20 Insertion Mutations+1 more
ORIC Pharmaceuticals76 enrolled4 locationsNCT06816992